Mol Med: Special endogenous protein HMGB1 or key role in COVID-19 and pneumonia

May 12, 2020 /PRNewswire
BIOON/ -- In a recent study published in the international journal Molecular Medicine , scientists from the Caroline Institute in Sweden and others found that in patients with severe COVID-19, a large amount of the endogenous protein HMGB1 released from the lungs may promote inflammation and tissue damage to the lungs; image source: CC0 Public Domain multiple viral infections promote the body's immune system to overreact to invasive infectious factors, resulting in a large number of special proteins called cytokine storms, which can then lead to severe, potentially fatal inflammation and tissue damage in patients, one of the main molecules in cytokine storms is the inflammatory protein HMGB1, in this article, researchers reveal the mechanisms behind the inflammation of the body, including the presence of the body 'We found that HMGB1 may play a key role in the occurrence of acute lung damage, whatever the cause, so we are very interested in detecting whether a particular HMGB1 inhibitor can reduce inflammation and lung damage caused by the new coronavirus,' said researcher Professor Ulf Anderon, who has been studying HMGB1 for 20 years There are no special HMGB1 inhibitors tested in human organisms, but some drugs that can produce other biological effects and are approved can partially inhibit HMGB1, and they have not tested for the effectiveness of reducing inflammation in the body The researchers hope to analyze current drugs to see if they have the potential to slow down HMGB1-mediated body damage, and another focus is on finding special proteins that are neglected to develop specific inhibitors of HMGB1, which not only slow inflammation caused by COVID-19 but also treat lung damage caused by other infections In a 20-year trial of repeated animal synods, researchers found that special HMGB1 inhibitors showed great promise, and now researchers have developed fully humanized antibodies that target HMGB1, but they don't know whether these therapies can work in the human body and, if applicable, patientside side effects can be accepted According to researcher Anderon, there are many studies that are interested in analyzing whether HMGB1 can be used as a target for treating severe lung infections, and recent studies in mice have revealed that the sensitivity or gender difference sin of endothelial cells in mice is not enough, when oxygen is lacking, the endothelial cells in the lungs of female mice will die non-inflammatoryly, i.e apoptosis , which does not trigger the release of HMGB1, but from male body mice will experience inflammatory death Finally, the researchers say several studies have shown that arterial blood contains only 60 percent of the vein blood, which means that a large amount of HMGB1 remains in the circulation of the lungs (biovalleybioon.com) Original Origin: Ulf Anderon et al.
Extracellular HMGB1: a therapeutic target in evere d'amyn dyfod yn coVID-19?
, Molecular Medicine
(2020) DOI: 10.1186/10020-020-00172-4